Expression of cyclo-oxygenase-2 in gastrointestinal carcinoid tumors

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 8, 2006, Pages 1313-1319

  Mizuno, Shigeaki ^a   Kato, Kimitoshi ^a   Hashimoto, Akemi ^a   Sugitani, Masahiko ^a   Sheikh, Aleemuzzaman ^a   Komuro, Sachiko ^a   Jike, Toyoharu ^a   Iwasaki, Ariyoshi ^a   Arakawa, Yasuyuki ^a   Nemoto, Norimichi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Carcinoid tumor; Cyclo oxygenase; Gastrointestinal tract; Immunohistochemistry; Metastasis

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2;

ADULT; AGED; ARTICLE; CALCULATION; CARCINOID; CELL POPULATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DUODENUM TUMOR; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECTUM TUMOR; STAINING; TUMOR VOLUME;

EID: 33745871231     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.04153.x     Document Type: Article

References (28)

1. Soga J. Carcinoid tumors: a statistical analyis of a Japanese series of 3123 reported and 1180 autopsy cases. Acta. Med. Biol. (Niigata) 1994; 42: 87-102.
2. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79: 813-29.
3. Memon AM, Nelson H. Gastrointestinal carcinoid tumors: current management strategies. Dis. Colon Rectum 1997; 40: 1101-17.
4. Kulke MH, Mayer RJ. Carcinoid tumors. N. Engl. J. Med. 1999; 340: 858-68.
5. Lauffer JM, Zhang T, Modlin IM. Current status of gastrointestinal carcinoids. Aliment. Pharmacol. Ther. 1999; 13: 271-87.
6. Ganim RB, Norton JA. Recent advances in carcinoid pathogenesis, diagnosis and management. Surg. Oncol. 2000; 9: 173-9.
7. Oberg K. Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr. Opin. Oncol. 2002; 14: 38-45.
8. Parente L, Perretti M. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem. Pharmacol. 2003; 65: 153-9.
9. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 2003; 24: 96-102.
10. Bakhle YS. COX-2 and cancer: a new approach to an old problem. Br. J. Pharmacol. 2001; 134: 1137-50.
11. Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br. J. Pharmacol. 1999; 128: 1121-32.
12. Fujita M, Fukui H, Kusaka T, Ueda Y, Fujimori T. Immunohistochemical expression of COX-2 in colorectal adenomas. J. Gastroenterol. 2000; 35: 488-90.
13. Nakajima T, Hamanaka K, Fukuda T, Oyama T, Kashiwabara K, Sano T. Why is cyclooxygenase-2 expressed in neuroendocrine cells of the human alimentary tract? Pathol. Int. 1997; 47: 889-91.
14. Hegedus TJ, Falzon M, Margaretten N, Gazdar AF, Schuller HM. Inhibition of N-diethylnitrosamine metabolism by human lung cancer cell lines with features of well differentiated pulmonary endocrine cells. Biochem. Pharmacol. 1987; 36: 3339-43.
15. Sandler M, Karim SM, Williams ED. Prostaglandins in amine-peptide- secreting tumours. Lancet 1968; 2: 1053-4.
16. McLemore TL, Hubbard WC, Litterst CL et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 1988; 48: 3140-7.
17. Ohike N, Morohoshi T. Immunohistochemical analysis of cyclooxygenase (COX)-2 expression in pancreatic endocrine tumors: association with tumor progression and proliferation. Pathol. Int. 2001; 51: 770-7.
18. Detjen KM, Welzel M, Wiedenmann B, Rosewicz S. Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest. Int. J. Cancer 2003; 107: 844-53.
19. Hashimoto A, Oinuma T, Sheikh A, Kato K, Arakawa Y, Nemoto N. Enhanced cyclooxygenase-2 immunoreactivity in human rectal carcinoids. Nihon Univ. J. Med. 2002; 44: 173-82.
20. Remmele W, Schicketanz K-H. Immunohistochemical determination of estrogen and progesterone receptor content in human subjective gradings (IRS). Pathol. Res. Pract. 1993; 8: 227-45.
21. Khan KNM, Masferrer BM, Woerner R, Soslow R, Koki AT. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand. J. Gastroenterol. 2001; 8: 865-9.
22. Qiu DK, Ma X, Peng YS, Chen XY. Significance of cyclooxygenase-2 expression in human primary hepatocellular carcinoma. World J. Gastroenterol. 2002; 8: 815-17.
23. Koga H, Sakisaka S, Ohishi M et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999; 29: 688-96.
24. Sano H, Kawahito Y, Wilder RL et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995; 55: 3785-9.
25. Evers BM, Townsend CM Jr, Upp JR et al. Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology 1991; 101: 303-11.
26. Funakoshi A, Tateishi K, Tsuru M et al. Pancreastatin producing cell line from human pancreatic islet cell tumor. Biochem. Biophys. Res. Commun. 1990; 168: 741-6.
27. Lundqvist M, Mark J, Funa K et al. Characterisation of a cell line (LCC-18) from a cultured human neuroendocrine-differentiated colonic carcinoma. Eur. J. Cancer 1991; 27: 1663-8.
28. Naribayashi-Inomoto Y, Ding M, Nakata H et al. Copresence of prostaglandin EP2 and EP3 receptors on gastric enterochromaffin-like cell carcinoid in African rodents. Gastroenterology 1995; 109: 341-7.